Further to this a biomarker that accurately quantifies HIF2α-HIF1β interaction could provide a useful tool to determine patients with solid tumours other than ccRCC that frequently exhibit hypoxia and may be sensitive to HIF2α inhibitors. This evidence concerns the gene ARNT and nonpapillary renal cell carcinoma.